Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| 7.75 | |
| 7.99 | |
| - | |
| 8.075 | |
| 7.74 | |
| 5.67-14.835 | |
| 304 M | |
| 38 816 K | |
| 72 994 K | |
| 0.624 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Pulmonx Corp (NASDAQ:LUNG), a company specializing in medical devices for the treatment of pulmonary disorders, has reported an insider sell according to a recent SEC filing. The insider, President an...
The Honest Company, Inc. LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-de...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
